H.B. Fuller Company (FUL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. While there are positive elements such as strong performance in medical-grade adhesives and strategic pricing actions, challenges persist with volume declines, inflationary pressures, and raw material supply issues. The company's guidance suggests modest revenue growth, but flat organic growth and a cautious economic environment indicate limited upside. The Q&A reveals concerns about raw material costs and geopolitical impacts, which temper optimism. Given the market cap, the stock is likely to experience a neutral reaction, with a price movement between -2% to 2%.
Key Financial Performance
Organic Revenue Decreased 6.6% year-on-year due to positive pricing being offset by lower volume.
EBITDA $119 million, increased 4% year-on-year. EBITDA margin expanded 90 basis points to 15.4%, driven by restructuring savings, positive pricing, and raw material cost actions.
EA Organic Revenue Increased approximately 3% excluding the impact of exiting the lower-margin solar business. Including solar, organic revenue declined 2%. EBITDA increased 9%, and EBITDA margin increased 120 basis points to 19.9%, driven by favorable pricing, raw material cost actions, and restructuring.
HHC Organic Revenue Declined 10% year-over-year due to tighter customer inventory levels and a shift from premium products to lower-cost alternatives. EBITDA margins were 13.9%, up 120 basis points, reflecting pricing, raw material cost actions, and expense control.
BAS Organic Sales Decreased 5.1% year-on-year. EBITDA decreased 1%, and EBITDA margins were flat as positive pricing, raw material actions, and restructuring savings were offset by volume declines.
Americas Organic Revenue Down 4% year-on-year. Declines in HHC were partially offset by EA, which achieved 8% organic revenue growth driven by aerospace and general industries.
EIMEA Organic Revenue Decreased 11% year-on-year due to tighter customer inventory management in HHC, weak construction market in BAS, and a tough comparison to the first quarter of 2025.
Asia Pacific Organic Revenue Up 2% excluding solar, lower than trend due to the timing of Chinese New Year.
Adjusted Gross Profit Margin 31.3%, up 170 basis points year-on-year due to positive pricing, raw material actions, and restructuring savings offsetting volume declines.
Adjusted Selling, General and Administrative Expense (SG&A) Up 4% year-over-year. Excluding acquisitions and foreign exchange, SG&A was down slightly due to diligent expense management.
Adjusted Earnings Per Share (EPS) $0.57, up 6% year-on-year driven by higher operating income and lower shares outstanding.
Cash Flow from Operations Improved $49 million year-on-year.
Net Debt to Adjusted EBITDA 3.1x, consistent with fiscal year-end 2025 and down from 3.5x at the end of the first quarter of last year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Market Share Gains: The company is leveraging supply chain disruptions caused by the Middle East conflict to support existing customers and gain market share. This includes securing raw materials ahead of competitors and implementing a minimum 10% price increase globally.
Restructuring Savings: Continued savings from Project Quantum Leap contributed to margin expansion and profitability improvements.
Supply Chain Management: Swift actions were taken to mitigate supply chain disruptions, including securing raw materials, reallocating volumes, and pursuing substitutes. These efforts helped offset inflationary pressures and raw material shortages.
Cost Management: Disciplined cost management led to improved EBITDA margins across segments despite volume declines.
Pause on M&A: The company has temporarily paused mergers and acquisitions to focus on share repurchases and achieving a target net debt to EBITDA ratio of 2.5x to 3x.
Long-term Competitiveness: Project Quantum Leap is progressing well, aiming to redesign the plant and supply chain network to enhance long-term competitiveness and profitability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Disruption: The conflict in the Middle East has caused significant constraints on raw material availability, impacting feedstocks, intermediates, logistics lanes, and energy inputs. Over 40 force majeure letters from suppliers indicate major disruptions, with chemical production capacity reduced and tanker routes disrupted. This is expected to lead to broad-based inflationary pressures and raw material shortages, with aftershocks persisting throughout the year.
Volume Declines: Organic revenue decreased by 6.6% year-on-year due to lower volumes, despite positive pricing. Specific segments like HHC and BAS experienced significant volume declines, reflecting tighter customer inventory management, affordability pressures, and challenging weather conditions.
Economic and Consumer Pressures: In the HHC segment, customers are maintaining tighter inventory levels, and consumers are shifting away from premium products to lower-cost alternatives and smaller package sizes due to ongoing affordability pressures.
Geopolitical and Market Volatility: The ongoing conflict in the Middle East has created elevated volatility in supply chains and markets, with potential long-term impacts on transportation, logistics, and raw material availability.
Strategic Execution Risks: The company has paused M&A activities in the near term due to petrochemical market disruptions and uncertainty, which could impact long-term growth strategies.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Net Revenue Growth: Net revenue for fiscal 2026 is expected to increase mid-single digits, with organic revenue projected to grow low single digits compared to fiscal 2025. Foreign currency translation is anticipated to positively impact revenue by 1% to 2%.
Adjusted EBITDA: Adjusted EBITDA for fiscal 2026 is forecasted to range between $645 million and $675 million. For the second quarter, adjusted EBITDA is expected to be between $175 million and $185 million.
Adjusted EPS: Adjusted earnings per share (EPS) for fiscal 2026 is projected to be in the range of $4.55 to $4.90.
Capital Allocation: Short-term capital allocation priorities have shifted due to petrochemical market disruptions. While strategic acquisitions remain a focus, the company will pause on closing deals in the near term and prioritize share repurchases. The target for net debt to EBITDA remains at 2.5x to 3x.
Market Share and Pricing Actions: The company has implemented a minimum 10% price increase across all product lines globally, effective April 1, with higher adjustments in certain regions and technologies. These actions aim to offset supply chain inflation and gain market share amidst competitor supply uncertainties.
Supply Chain and Raw Material Impact: The ongoing Middle East conflict is expected to cause significant raw material shortages and inflationary pressures throughout 2026. Supply chain disruptions are anticipated to persist even if the conflict resolves, with aftershocks affecting logistics and production cycles.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company has updated its short-term capital allocation priorities due to the current petrochemical market disruption and uncertainty. While M&A remains a cornerstone of their growth strategy, they have decided to pause on closing deals in the near term. Instead, they will focus more cash deployment on share repurchases, while working towards achieving their target of 2.5x to 3x net debt to EBITDA.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does the 10% price hike and guidance raise still hold given raw material constraints and pricing?
A:The company is baking in additional price and raw material benefits but also anticipates negative volume impacts. They see this as a sustainable market reset due to thin supplier margins and capacity reductions. They are prioritizing raw material acquisition and selective customer partnerships to gain market share.
Q:Did inventory management in HHC worsen in January and February, and what is the impact on organic growth?
A:Inventory management is occurring at both big customers and distributors, with smaller customers impacted by tariffs and inflation. Consumers are switching to less premium products, leading to reduced adhesive usage. Organic growth in HHC has been pressured due to these factors.
Q:What was the impact of Lunar New Year on Q1 performance, and how is activity in China and Asia post-Lunar New Year?
A:The Lunar New Year caused a $15-$20 million revenue impact in Q1, which is expected to shift to Q2. Excluding this, China showed double-digit growth in Q1. The company has redirected capacity in China to higher-end products like fem care and adult incontinence, which performed well.
Q:Are there concerns about raw material supply availability, and what is the timing of inflationary impacts?
A:The company has received over 40 force majeure notices, mainly from Asia Pacific. Raw material costs have increased significantly, with some categories seeing price hikes of 10%-50%. Inflationary impacts are already being experienced, and the company is proactively managing supply and pricing.
Q:Is the 10% price hike a first step, and will there be additional pricing actions?
A:Yes, the 10% price hike is a first step. The company anticipates further pricing actions throughout the year as they monitor raw material categories and inflationary pressures.
Q:What are the updated volume and pricing expectations for the year, and how do they vary across segments?
A:The company expects pricing to increase by 7%-8% and volumes to decline by 5%-6%. Volume impacts are expected to be consistent across segments, with share gains offset by demand destruction. Pricing actions are uniform across all segments.
Q:Where are the greatest opportunities for market share gains, and how can these gains be made durable?
A:Opportunities for share gains are significant in HHC and higher-margin spaces like EA and BAS. The company is securing long-term agreements with customers and leveraging strong supplier relationships to make these gains durable.
Q:What are the cash flow prospects for 2026, and what factors influence them?
A:The company is comfortable with its cash flow guidance but is monitoring inventory management closely. Flexibility in inventory levels may be required to ensure supply assurance.
Q:Why has the volume outlook changed from negative 1% to negative 5%?
A:The change is due to a combination of share gains, potential customer difficulties in obtaining other materials, and global demand erosion in an inflationary environment.
Q:Is Europe a particular concern for volume impacts due to rising energy costs?
A:The impact is broad-based, but Europe and Asia face more challenges due to energy and feedstock availability. The U.S. is relatively more self-sufficient.
Q:What are the cost reduction aspirations for the year, and what has been achieved so far?
A:The company has increased its cost reduction target from $10 million to $15 million for the year, driven by restructuring actions and volume reductions.
Q:What is the impact of solar-related revenues, and when will it stabilize?
A:Solar-related revenues were down 40% in the quarter, impacting overall revenue by 1%. This segment is expected to stabilize by Q3.
Q:What is the performance of the medical-grade adhesives business, and what is its size?
A:The medical-grade adhesives business in Europe grew by almost 20% organically in the quarter. While still small, it is growing rapidly.
Q:Will the medical-grade adhesives segment be affected by oil price increases?
A:The impact is expected to be minimal due to the small amount of material used in these products.
Q:Can the company achieve its 20% EBITDA margin target by 2028?
A:Yes, the company remains on track to achieve its 20% EBITDA margin target by 2028.
Q:What are the order trends exiting Q1, and is there evidence of prebuying or hoarding?
A:March showed higher revenue and improved margins. Customers are anxious to place orders, but the company is avoiding facilitating hoarding.
Q:Are there specific GBUs more impacted by customers' inability to procure raw materials?
A:No specific GBUs are currently impacted, but the company anticipates potential issues and is prepared to work with customers on reformulations.
Q:What is the update on recent acquisitions, particularly in medical-grade adhesives?
A:The medical-grade adhesives business in Europe performed strongly, growing by almost 20% organically. The company does not disclose the size of this segment.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the size of the medical-grade adhesives segment, citing that it is still small but growing rapidly. Additionally, they did not elaborate on the exact timing or steps to achieve the 20% EBITDA margin target by 2028, only reaffirming their commitment to the goal.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
EA margin
EIMEA customer
East action
East implication
Fuller summary
Fuller volatility
HHC construction
HHC environment
Jensen Investor
Leap price
Mastin President
Mastin today
Middle East
New supply
Officer Executive
Pacific trend
Relations statement
acquisition closing
action saving
aerospace
allocation
commitment
comparison
condition
conflict
cost action
digit
disruption
industry market
inventory
logistics
market share
material action
pressure
price material
restructuring saving
saving volume
shock
supplier
supply chain
volume decline
FUL Transcript
H.B. Fuller Company (FUL) Q2 2026 Earnings Call Transcript
Neutral6-25
H.B. Fuller Company (FUL) Q1 2026 Earnings Call Transcript
Unknown3-26
The earnings call presents a mixed outlook. While there are positive elements such as strong performance in medical-grade adhesives and strategic pricing actions, challenges persist with volume declines, inflationary pressures, and raw material supply issues. The company's guidance suggests modest revenue growth, but flat organic growth and a cautious economic environment indicate limited upside. The Q&A reveals concerns about raw material costs and geopolitical impacts, which temper optimism. Given the market cap, the stock is likely to experience a neutral reaction, with a price movement between -2% to 2%.
H.B. Fuller Company (FUL) Q4 2025 Earnings Call Transcript
Unknown1-15
The earnings call presents a mixed picture. While strong financial metrics and reduced leverage are positive, the weak Q1 guidance due to the Chinese New Year and challenges in key segments dampen sentiment. The Q&A reveals cautious optimism with positive pricing and raw material benefits, but concerns about construction and packaging markets persist. The market cap suggests moderate volatility, leading to a neutral sentiment as positives and negatives balance out.
H.B. Fuller Company (FUL) Q3 2025 Earnings Call Transcript
Positive9-25
The earnings call highlighted a positive sentiment with increased adjusted gross profit margin, EPS, and operating cash flow. Despite some regional revenue declines, the EA business showed strong growth. The Q&A revealed management's optimism about future growth, especially in EA and medical adhesives, and successful pricing strategies. Although cash flow guidance was lowered due to temporary inventory levels, the overall financial health and strategic focus on high-margin areas like data centers indicate a positive outlook.
FUL Slides
FUL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
